Lichen sclerosus et atrophicus induced by carbamazepine: a case report

Int J Immunopathol Pharmacol. 2013 Jul-Sep;26(3):791-4. doi: 10.1177/039463201302600326.

Abstract

We report a case of Lichen Sclerosus in a 73-year-old man who had been treated for epilepsy with carbamazepine. Lichen sclerosus et atrophicus (LSA), also called lichen sclerosus (LS), is a chronic inflammatory cutaneous condition characterized by white plaques with epidermal atrophy and scarring. To date no cases of LSA has been linked to carbamazepine, although in a few cases lichenoid eruptions but without sclero-atrophy have been described after exposure to this drug. Therefore, to our knowledge, this is the first report of a Lichen sclerosus et atrophicus induced by carbamazepine.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Administration, Topical
  • Aged
  • Anticonvulsants / adverse effects*
  • Carbamazepine / adverse effects*
  • Carbamazepine / analogs & derivatives
  • Carbamazepine / therapeutic use
  • Drug Eruptions / diagnosis
  • Drug Eruptions / drug therapy
  • Drug Eruptions / etiology*
  • Drug Substitution
  • Epilepsy, Tonic-Clonic / drug therapy*
  • Humans
  • Lichen Sclerosus et Atrophicus / chemically induced*
  • Lichen Sclerosus et Atrophicus / diagnosis
  • Lichen Sclerosus et Atrophicus / drug therapy
  • Male
  • Steroids / administration & dosage
  • Treatment Outcome

Substances

  • Anticonvulsants
  • Steroids
  • oxcarbamazepine
  • Carbamazepine